Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

GlycoMimetics

Nasdaq:GLYC
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
GLYC
Nasdaq
$101M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The last earnings update was 29 days ago. More info.


Add to Portfolio Compare Print
  • GlycoMimetics has significant price volatility in the past 3 months.
GLYC Share Price and Events
7 Day Returns
11.5%
NasdaqGM:GLYC
5.2%
US Biotechs
10.5%
US Market
1 Year Returns
-81.4%
NasdaqGM:GLYC
0%
US Biotechs
-11.5%
US Market
GLYC Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
GlycoMimetics (GLYC) 11.5% -33.5% -59.3% -81.4% -57.3% -72%
US Biotechs 5.2% -6.5% -8.7% 0% 6.2% -10.4%
US Market 10.5% -15.4% -21.4% -11.5% 5.4% 18.1%
1 Year Return vs Industry and Market
  • GLYC underperformed the Biotechs industry which returned 0% over the past year.
  • GLYC underperformed the Market in United States of America which returned -11.5% over the past year.
Price Volatility
GLYC
Industry
5yr Volatility vs Market
Related Companies

Value

 Is GlycoMimetics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of GlycoMimetics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for GlycoMimetics.

NasdaqGM:GLYC Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year US Government Bond Rate 1.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:GLYC
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 1.7%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.2
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.2 (1 + (1- 21%) (3.58%))
1.157
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.16
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.74% + (1.157 * 5.44%)
8.03%

Discounted Cash Flow Calculation for NasdaqGM:GLYC using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for GlycoMimetics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NasdaqGM:GLYC DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.03%)
2020 -68.10 Analyst x1 -63.04
2021 -51.55 Analyst x2 -44.17
2022 -49.70 Analyst x2 -39.42
2023 -25.25 Analyst x2 -18.54
2024 13.10 Analyst x2 8.90
2025 14.61 Est @ 11.53% 9.19
2026 15.87 Est @ 8.59% 9.24
2027 16.90 Est @ 6.54% 9.11
2028 17.76 Est @ 5.1% 8.86
2029 18.49 Est @ 4.09% 8.54
Present value of next 10 years cash flows $-111.00
NasdaqGM:GLYC DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $18.49 × (1 + 1.74%) ÷ (8.03% – 1.74%)
$298.92
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $298.92 ÷ (1 + 8.03%)10
$138.03
NasdaqGM:GLYC Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $-111.00 + $138.03
$27.03
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $27.03 / 43.58
$0.62
NasdaqGM:GLYC Discount to Share Price
Calculation Result
Value per share (USD) From above. $0.62
Current discount Discount to share price of $2.32
= -1 x ($2.32 - $0.62) / $0.62
-274%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of GlycoMimetics is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for GlycoMimetics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are GlycoMimetics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:GLYC PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.34
NasdaqGM:GLYC Share Price ** NasdaqGM (2020-03-27) in USD $2.32
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.4x
United States of America Market PE Ratio Median Figure of 2,939 Publicly-Listed Companies 12.96x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of GlycoMimetics.

NasdaqGM:GLYC PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:GLYC Share Price ÷ EPS (both in USD)

= 2.32 ÷ -1.34

-1.73x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • GlycoMimetics is loss making, we can't compare its value to the US Biotechs industry average.
  • GlycoMimetics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does GlycoMimetics's expected growth come at a high price?
Raw Data
NasdaqGM:GLYC PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.73x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
11.5%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.96x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for GlycoMimetics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on GlycoMimetics's assets?
Raw Data
NasdaqGM:GLYC PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $3.55
NasdaqGM:GLYC Share Price * NasdaqGM (2020-03-27) in USD $2.32
United States of America Biotechs Industry PB Ratio Median Figure of 429 Publicly-Listed Biotechs Companies 2.53x
United States of America Market PB Ratio Median Figure of 5,148 Publicly-Listed Companies 1.26x
NasdaqGM:GLYC PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:GLYC Share Price ÷ Book Value per Share (both in USD)

= 2.32 ÷ 3.55

0.65x

* Primary Listing of GlycoMimetics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • GlycoMimetics is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess GlycoMimetics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. GlycoMimetics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is GlycoMimetics expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
11.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is GlycoMimetics expected to grow at an attractive rate?
  • Unable to compare GlycoMimetics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare GlycoMimetics's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare GlycoMimetics's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:GLYC Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:GLYC Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 11.5%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:GLYC Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:GLYC Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 104 -18 5
2023-12-31 64 -26 -42 5
2022-12-31 13 -60 -73 5
2021-12-31 2 -68 -70 5
2020-12-31 0 -56 -63 5
2020-03-28
NasdaqGM:GLYC Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -52 -58
2019-09-30 -49 -57
2019-06-30 -46 -55
2019-03-31 -47 -51
2018-12-31 -43 -48
2018-09-30 -42 -44
2018-06-30 -38 -40
2018-03-31 -31 -37
2017-12-31 -30 -33
2017-09-30 0 -27 -32
2017-06-30 0 -29 -32
2017-03-31 0 -30 -32

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • GlycoMimetics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if GlycoMimetics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:GLYC Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from GlycoMimetics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:GLYC Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -0.67 0.19 -1.77 3.00
2023-12-31 -0.91 0.21 -1.71 3.00
2022-12-31 -1.48 -0.92 -1.90 6.00
2021-12-31 -1.48 -1.04 -2.09 6.00
2020-12-31 -1.45 -1.18 -1.60 5.00
2020-03-28
NasdaqGM:GLYC Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.34
2019-09-30 -1.32
2019-06-30 -1.28
2019-03-31 -1.18
2018-12-31 -1.18
2018-09-30 -1.12
2018-06-30 -1.10
2018-03-31 -1.14
2017-12-31 -1.13
2017-09-30 -1.21
2017-06-30 -1.33
2017-03-31 -1.44

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if GlycoMimetics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess GlycoMimetics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
GlycoMimetics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has GlycoMimetics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare GlycoMimetics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • GlycoMimetics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare GlycoMimetics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare GlycoMimetics's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
GlycoMimetics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from GlycoMimetics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:GLYC Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -57.89 14.36 47.03
2019-09-30 -57.07 13.41 47.60
2019-06-30 -55.40 12.82 46.61
2019-03-31 -50.84 11.92 42.84
2018-12-31 -48.27 11.41 40.09
2018-09-30 -43.62 11.31 34.77
2018-06-30 -40.00 10.92 30.82
2018-03-31 -36.86 10.60 27.24
2017-12-31 -33.28 9.83 24.10
2017-09-30 0.00 -32.35 9.31 23.44
2017-06-30 0.02 -32.26 8.90 23.58
2017-03-31 0.02 -32.19 8.69 23.64
2016-12-31 0.02 -31.81 8.65 23.28
2016-09-30 0.05 -32.36 8.31 24.18
2016-06-30 0.04 -31.68 8.46 23.30
2016-03-31 20.07 -13.22 7.96 25.36
2015-12-31 20.07 -12.77 7.81 25.05
2015-09-30 20.04 -11.28 7.96 23.37
2015-06-30 20.04 -10.73 7.48 23.38
2015-03-31 15.03 -13.13 7.28 20.90
2014-12-31 15.03 -11.12 6.60 19.57
2014-09-30 15.10 -7.60 5.30 17.41
2014-06-30 15.16 -4.68 4.45 15.31
2014-03-31 0.19 -16.17 3.52 12.84
2013-12-31 3.99 -10.61 2.90 11.70
2013-09-30 7.80 -6.10 2.59 11.31
2013-06-30 11.58 -1.58 2.34 10.81
2013-03-31 15.29 3.02 2.22 10.05

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if GlycoMimetics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if GlycoMimetics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if GlycoMimetics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess GlycoMimetics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
GlycoMimetics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is GlycoMimetics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up GlycoMimetics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • GlycoMimetics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • GlycoMimetics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of GlycoMimetics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • GlycoMimetics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from GlycoMimetics Company Filings, last reported 2 months ago.

NasdaqGM:GLYC Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 154.20 0.00 158.20
2019-09-30 167.08 0.00 170.89
2019-06-30 178.56 0.00 184.17
2019-03-31 192.79 0.00 195.56
2018-12-31 205.46 0.00 209.92
2018-09-30 218.10 0.00 219.83
2018-06-30 227.99 0.00 229.43
2018-03-31 238.04 0.00 242.63
2017-12-31 119.70 0.00 123.92
2017-09-30 108.56 0.00 112.87
2017-06-30 115.43 0.00 119.15
2017-03-31 31.89 0.00 34.60
2016-12-31 35.30 0.00 40.05
2016-09-30 41.75 0.00 45.28
2016-06-30 48.88 0.00 53.09
2016-03-31 34.77 0.00 38.84
2015-12-31 40.47 0.00 46.81
2015-09-30 48.70 0.00 53.77
2015-06-30 55.22 0.00 40.25
2015-03-31 44.36 0.00 46.58
2014-12-31 50.80 0.00 55.22
2014-09-30 57.71 0.00 61.36
2014-06-30 63.88 0.00 66.22
2014-03-31 55.35 0.00 56.97
2013-12-31 2.91 0.00 2.31
2013-09-30 6.52 0.00 7.69
2013-06-30 9.74 0.00 10.78
2013-03-31 12.53 0.00 17.37
  • GlycoMimetics has no debt.
  • GlycoMimetics currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • GlycoMimetics has sufficient cash runway for more than 3 years based on current free cash flow.
  • GlycoMimetics has sufficient cash runway for 2.8 years if free cash flow continues to grow at historical rates of 30.6% each year.
X
Financial health checks
We assess GlycoMimetics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. GlycoMimetics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is GlycoMimetics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from GlycoMimetics dividends.
If you bought $2,000 of GlycoMimetics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate GlycoMimetics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate GlycoMimetics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:GLYC Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1949 Stocks 3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:GLYC Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as GlycoMimetics has not reported any payouts.
  • Unable to verify if GlycoMimetics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of GlycoMimetics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as GlycoMimetics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess GlycoMimetics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can GlycoMimetics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. GlycoMimetics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of GlycoMimetics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Rachel King
COMPENSATION $3,185,153
AGE 60
TENURE AS CEO 17.2 years
CEO Bio

Mrs. Rachel K. King co-founded Glycomimetics, Inc. in 2003 and has been its Chief Executive Officer and its President since 2003. She has been a Director of Novavax, Inc. since November 1, 2018. Mrs. King joined the Novavax Board in 2018. Mrs. King served as an Executive in Residence at New Enterprise Associates (NEA) from 2001 to 2003. She served as a Senior Vice President of Novartis Corporation from 1999 to 2001. She served as an executive with Genetic Therapy, Inc. for ten years. At GTI, Mrs. King held various roles, including serving as its Chief Executive Officer. Mrs. King worked at ALZA Corporation in Palo Alto, California and at Bain and Company in Boston. She serves as a Vice Chairman of Health Section at the Biotechnology Industry Organization (BIO). She serves as a Director of Biotechnology Innovation Organization. She has been a Director of Warp Drive Bio, LLC since July 2016. She serves on the Dean's Council of the Harvard School of Public Health and on the Board of Imagination Stage. She has been a Director of GlycoMimetics, Inc. since 2003. She served as a Director of MDBio, Inc. Mrs. King received her B.A. degree from Dartmouth College and her MBA degree from Harvard Business School. She served as Chair of the Maryland Life Sciences Advisory Board from 2013 to 2015. She also serves on the Board of the University of Maryland BioPark.

CEO Compensation
  • Rachel's compensation has increased whilst company is loss making.
  • Rachel's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the GlycoMimetics management team in years:

7
Average Tenure
50.5
Average Age
  • The average tenure for the GlycoMimetics management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Rachel King

TITLE
President
COMPENSATION
$3M
AGE
60
TENURE
17.2 yrs

Brian Hahn

TITLE
Senior VP
COMPENSATION
$1M
AGE
45
TENURE
8.2 yrs

John Magnani

TITLE
Senior VP of Research & Chief Scientific Officer
COMPENSATION
$2M
AGE
66
TENURE
17.2 yrs

Helen Thackray

TITLE
Senior VP of Clinical Development & Chief Medical Officer
COMPENSATION
$2M
AGE
51
TENURE
14.2 yrs

Stephanie Irish

TITLE
Vice President of Accounting
AGE
48
TENURE
1.2 yrs

Henry Flanner

TITLE
Vice President of Technical Operations
TENURE
3.7 yrs

Christian Dinneen-Long

TITLE
VP, Corporate Counsel & Corporate Secretary
TENURE
0.9 yrs

Armand Girard

TITLE
Senior Vice President of Strategy and Corporate Development
AGE
50
TENURE
5.9 yrs
Board of Directors Tenure

Average tenure and age of the GlycoMimetics board of directors in years:

3.5
Average Tenure
62.5
Average Age
  • The tenure for the GlycoMimetics board of directors is about average.
Board of Directors

Tim Pearson

TITLE
Chairman of the Board
COMPENSATION
$196K
AGE
51
TENURE
0.8 yrs

Rachel King

TITLE
President
COMPENSATION
$3M
AGE
60
TENURE
17.2 yrs

John Magnani

TITLE
Senior VP of Research & Chief Scientific Officer
COMPENSATION
$2M
AGE
66
TENURE
17.2 yrs

Mark Goldberg

TITLE
Independent Director
COMPENSATION
$190K
AGE
65
TENURE
5.7 yrs

Dan Junius

TITLE
Independent Director
COMPENSATION
$192K
AGE
67
TENURE
4 yrs

Scott Koenig

TITLE
Independent Director
COMPENSATION
$180K
AGE
67
TENURE
3 yrs

Pat Andrews

TITLE
Independent Director
COMPENSATION
$184K
AGE
60
TENURE
2.8 yrs

Scott Jackson

TITLE
Director
COMPENSATION
$172K
AGE
54
TENURE
1.3 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by GlycoMimetics individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
10. Mar 20 Buy Daniel Junius Individual 09. Mar 20 09. Mar 20 20,000 $3.40 $68,000
09. Sep 19 Buy BVF Partners LP Company 05. Sep 19 05. Sep 19 1,668,746 $3.18 $5,309,950
15. Aug 19 Buy Daniel Junius Individual 13. Aug 19 13. Aug 19 10,000 $3.18 $31,800
X
Management checks
We assess GlycoMimetics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. GlycoMimetics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

The GlycoMimetics (NASDAQ:GLYC) Share Price Has Gained 87% And Shareholders Are Hoping For More

With zero revenue generated over twelve months, we don't think that GlycoMimetics has proved its business plan yet. … It seems likely some shareholders believe that GlycoMimetics has the funding to invent a new product before too long. … Some GlycoMimetics investors have already had a taste of the sweet taste stocks like this can leave in the mouth, as they gain popularity and attract speculative capital.

Simply Wall St -

What Should We Expect From GlycoMimetics, Inc.'s (NASDAQ:GLYC) Earnings Over The Next Few Years?

GlycoMimetics, Inc.'s (NASDAQ:GLYC) latest earnings announcement in December 2018 … that losses became smaller relative to the prior year's level

Simply Wall St -

Have Insiders Been Selling GlycoMimetics, Inc. (NASDAQ:GLYC) Shares This Year?

So shareholders might well want to know whether insiders have been buying or selling shares in GlycoMimetics, Inc. … As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.'. … Brian Hahn was the only individual insider to sell shares in the last twelve months

Simply Wall St -

Why GlycoMimetics, Inc. (NASDAQ:GLYC) Is An Attractive Investment To Consider

(NASDAQ:GLYC) is a company with exceptional fundamental characteristics. … Upon building up an investment case for a stock, we should look at various aspects. … In the case of GLYC, it

Simply Wall St -

GlycoMimetics Inc (NASDAQ:GLYC) Is Expected To Breakeven

The US$673.91m market-cap posted a loss in its most recent financial year of -US$33.28m and a latest trailing-twelve-month loss of -US$36.86m leading to an even wider gap between loss and breakeven? … The most pressing concern for investors is GLYC’s path to profitability – when will it breakeven

Simply Wall St -

Will GlycoMimetics Inc's (NASDAQ:GLYC) Earnings Grow Over The Couple Of Years?

GlycoMimetics Inc's (NASDAQ:GLYC) most recent earnings announcement in September 2017 indicated that losses became smaller relative to the prrior year's level as a result of recent tailwinds Below is a brief commentary on my key takeaways on how market analysts view GlycoMimetics's earnings growth outlook over the next few years and whether the future looks brighter. … NasdaqGM:GLYC Future Profit Jan 2nd 18 Even though it is helpful to be aware of the growth year by year relative to today’s figure, it may be more beneficial analyzing the rate at which the business is moving every year, on average. … The slope of this line is the rate of earnings growth, which in this case is 31.89%.

Simply Wall St -

How GlycoMimetics Inc's (NASDAQ:GLYC) EPS Growth Stacks Up Against Industry Performance

View our latest analysis for GlycoMimetics Commentary On GLYC's Past Performance For the purpose of this commentary, I like to use the ‘latest twelve-month’ data, which annualizes the most recent half-year data, or in some cases, the latest annual report is already the most recent financial year data. … For GlycoMimetics, the latest earnings -$32.4M, which compared to the prior year's level, has become less negative. … Eyeballing growth from a sector-level, the US biotechnology industry has been growing its average earnings by double-digit 11.07% in the previous year, and 20.18% over the past five years.

Simply Wall St -

Company Info

Description

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company’s advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and is in a Phase III clinical trial, conducted by its strategic collaboration with Pfizer Inc. It is also developing uproleselan, an E-selectin antagonist that is evaluated in a Phase I/II clinical trial as a potential treatment for acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML. In addition, the company offers GMI-1359 that has completed Phase I clinical trial to target E-selectin and a chemokine receptor for various tumor types. Further, it is developing various other programs, including GMI-1687, an antagonist of E-selectin; and Galectin-3, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.

Details
Name: GlycoMimetics, Inc.
GLYC
Exchange: NasdaqGM
Founded: 2003
$101,112,511
43,582,979
Website: http://www.glycomimetics.com
Address: GlycoMimetics, Inc.
9708 Medical Center Drive,
Rockville,
Maryland, 20850,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM GLYC Common Stock Nasdaq Global Market US USD 10. Jan 2014
DB GKO Common Stock Deutsche Boerse AG DE EUR 10. Jan 2014
BRSE GKO Common Stock Berne Stock Exchange CH CHF 10. Jan 2014
Number of employees
Current staff
Staff numbers
57
GlycoMimetics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 04:35
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/27
Last earnings filing: 2020/02/28
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.